03 febbraio 2021 12:02 Fonte: Adnkronos #salute-e-benessere THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system. The clinical development of engineered T-cell treatments is moving ahead and the EU has already approved this therapy for the treatment of leukemia. Despite its potential to cure many types of cancers and other infectious or autoimmune diseases, the translation into clinical trials and entry into the EU market is slow and lagging behind other regions. There is a lack of (1) standardized safety and efficacy prediction models, (2) strategies for optimal patient conditioning, and (3) customized manufacturing, release, and monitoring schemes.